Lincomycin
Lincocin, Lincomycin (lincomycin) is a small molecule pharmaceutical. Lincomycin was first approved as Lincocin on 1982-01-01. It is used to treat pneumococcal infections and staphylococcal infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Lincocin, Lincomycin (discontinued: Lincocin, Lincomycin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lincocin | New Drug Application | 2025-03-10 |
| lincomycin | ANDA | 2024-10-16 |
| lincomycin hydrochloride | ANDA | 2022-09-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pneumococcal infections | EFO_0000772 | D011008 | J13 |
| staphylococcal infections | — | D013203 | A49.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2010 | Injection, lincomycin hcl, up to 300 mg |
Clinical
Clinical Trials
154 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 8 | 2 | 10 | 16 | — | 35 |
| Infections | D007239 | EFO_0000544 | — | 2 | 3 | 6 | 6 | 6 | 21 |
| Staphylococcal infections | D013203 | — | A49.01 | — | 2 | 3 | 3 | 3 | 10 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | 1 | 1 | 3 | 4 | 1 | 10 |
| Bacterial infections | D001424 | — | A49 | 3 | — | 1 | 2 | 3 | 9 |
| Surgical wound infection | D013530 | — | — | — | 1 | — | 6 | 2 | 9 |
| Communicable diseases | D003141 | — | — | — | — | 3 | 2 | 3 | 8 |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | — | 1 | 3 | 5 |
| Wound infection | D014946 | — | — | — | — | — | 4 | — | 4 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 2 | 1 | 3 |
Show 45 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 3 | 4 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | 3 | 4 |
| Malaria | D008288 | EFO_0001068 | B54 | — | 1 | 2 | — | — | 3 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | 1 | 1 | — | 1 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | 1 | 2 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | 2 | — | — | 2 |
| Bacterial skin diseases | D017192 | — | — | — | — | 1 | — | 1 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | 1 | 2 |
| Nasal obstruction | D015508 | — | — | — | — | 1 | — | — | 1 |
| Nasal surgical procedures | D059747 | — | — | — | — | 1 | — | — | 1 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Exanthema | D005076 | — | — | — | 1 | — | — | — | 1 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
| Mandibular fractures | D008337 | — | S02.6 | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aids-related opportunistic infections | D017088 | — | — | — | — | — | — | 3 | 3 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 2 | 2 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 2 | 2 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | — | — | — | — | 2 | 2 |
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | — | — | — | — | 2 | 2 |
| Encephalitis | D004660 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lincomycin |
| INN | lincomycin |
| Description | Lincomycin is a carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis. It has a role as an antimicrobial agent and a bacterial metabolite. It is a carbohydrate-containing antibiotic, a S-glycosyl compound, a monocarboxylic acid amide, a pyrrolidinecarboxamide and a L-proline derivative. |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1 |
Identifiers
| PDB | — |
| CAS-ID | 154-21-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1447 |
| ChEBI ID | 6472 |
| PubChem CID | 3000540 |
| DrugBank | DB01627 |
| UNII ID | BOD072YW0F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lincomycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,361 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lincocin, Lincomycin, Lincomycin hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
256 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use